SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

SLC17A7

Vesicular glutamate transporter 1 (VGLUT1)

Score: 0.325 Price: $0.33 Medium Druggability Status: active Wiki: SLC17A7
HYPOTHESES
1
PAPERS
3
KG EDGES
10
DEBATES
0

3D Protein Structure

🧬 SLC17A7 — PDB 6V6E Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability
Medium
Score: 0.53
Clinical Stage
Phase III
Target Class
Transporter
Safety
0.60
Druggability Analysis
Drug Development0.45
Structural Tractability0.70
Target Class0.70
Safety Profile0.60
Key Metrics
PDB Structures:
2
Known Drugs:
3
Approved:
0
In Clinical Trials:
0
Drug Pipeline (3 compounds)
Druggability Rationale: SLC17A7 presents significant druggability challenges as a vesicular transporter with no known clinical drugs, a low druggability score (0.35), and limited structural data. Membrane transporters typically require innovative modulation approaches (allosteric modulators, protein stabilizers, or transcriptional activators) rather than conventional orthosteric inhibitors, and the lack of high-resolution structural information further constrains rational drug design.
Mechanism: Expression restoration — upregulating SLC17A7 transcription or stabilizing VGLUT1 protein to preserve excitatory synaptic function
Drug Pipeline (3 compounds)
Known Drugs:
Riluzole (Approved (ALS))
Troriluzole (Phase II/III)
Chicago Sky Blue 6B (Tool compound)
Structural Data:
PDB (2) ✓AlphaFold ✓Cryo-EM ✓
8LDG
UniProt: Q9P2U7

🧬 3D Protein Structure

🧬 SLC17A7 — PDB 6V6E Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is challenged by the presence of three VGLUT isoforms (VGLUT1, VGLUT2, VGLUT3) with overlapping tissue distribution and sequence homology. However, VGLUT1 predominance in cortical/hippocampal regions offers therapeutic window potential if isoform-selective modulators targeting unique structural elements can be developed.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active
3
Completed
5
Total Enrollment
2,384
By Phase
EARLY_PHASE1: 2 · PHASE2: 3 · PHASE3: 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Recruiting
PHASE3 NCT03127267 n=495
Amyotrophic Lateral Sclerosis
Interventions: Masitinib (6.0), Riluzole, Placebo
Sponsor: AB Science | Started: 2021-02-02
Methamphetamine and Troriluzole Recruiting
EARLY_PHASE1 NCT06989853 n=40
Methamphetamine Use Disorder
Interventions: Placebo, Methamphetamine
Sponsor: William Stoops | Started: 2025-08-25
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma Recruiting
EARLY_PHASE1 NCT06552260 n=27
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions: Troriluzole
Sponsor: Ugonma Chukwueke | Started: 2025-02-19
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) Completed
PHASE3 NCT01257828 n=270
Cervical Spondylotic Myelopathy
Interventions: riluzole, Placebo medication
Sponsor: AOSpine North America Research Network | Started: 2012-03
Randomized Trial of Adult Participants With Generalized Anxiety Disorder Completed
PHASE3 NCT03829241 n=881
Generalized Anxiety Disorder
Interventions: Troriluzole, Placebo
Sponsor: Biohaven Pharmaceuticals, Inc. | Started: 2019-02-19
Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) Completed
PHASE2 NCT00774423 n=141
SMA
Interventions: Riluzole
Sponsor: Assistance Publique - Hôpitaux de Paris | Started: 2006-01
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression Completed
PHASE2 NCT01204918 n=104
Depression
Interventions: Riluzole, placebo
Sponsor: Yale University | Started: 2011-06
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder Completed
PHASE2 NCT03299166 n=426
Obsessive-Compulsive Disorder
Interventions: Troriluzole, Placebo
Sponsor: Biohaven Pharmaceuticals, Inc. | Started: 2017-12-19

Linked Hypotheses (2)

Excitatory Neuron Vulnerability via SLC17A7 Downregulation0.675
Layer V excitatory neurons show selectively enhanced vulnerability through dysregulated calcium sign0.632

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Portfolio 0.00 (25%) Druggability 0.53 (20%) Evidence 0.65 (20%) Safety 0.60 (15%) Competitive 0.00 (10%) Connectivity 0.00 (10%) 0.325 composite

Knowledge Graph (20)

associated with (1)

SLC17A7→Cognitive function

binds to (1)

SLC17A7→L-glutamate

co-expressed with (1)

SLC17A7→SYNAPTOPHYSIN

co discussed (2)

NTRK2→SLC17A7SCN4B→SLC17A7

expressed in (4)

SLC17A7→SubiculumSLC17A7→Synaptic vesiclesSLC17A7→LAYER_3_NEURONSSLC17A7→LAYER_5_NEURONS

functionally coupled to (1)

SLC17A7→PSD95

implicated in (2)

SLC17A7→Excitatory postsynaptic injurySLC17A7→Epileptogenesis

involved in (2)

SLC17A7→Excitatory synaptic transmissionSLC17A7→Glutamate

loss correlates with (1)

SLC17A7→COGNITIVE_DECLINE

participates in (1)

SLC17A7→Glutamatergic Transmission / Synaptic Function

references (1)

VGLUT3 Protein→SLC17A7

regulates (2)

SLC17A7→Insulin signallingSLC17A7→Excitability

required for (1)

SLC17A7→LTP

Debate History (0)

No debates yet

← Back to Exchange | Dashboard